Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database.BMJ open · 2025
   Article
2. Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs.Pathogens (Basel, Switzerland) · 2024
   Review
3. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.Journal of clinical laboratory analysis · 2024
   Review
4. Real-life use of delamanid: results from the European post-authorisation safety study.IJTLD open · 2024
   Article
5. Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India.Journal of clinical tuberculosis and other mycobacterial diseases · 2024
   Article
6. Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.Cellular and molecular life sciences : CMLS · 2023
   Review
7. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
   Article
8. Journal of personalized medicine · 2022
   Review
9. Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017-2019.Public health action · 2021
   Article
10. New Drugs for the Treatment of Tuberculosis.Clinics in chest medicine · 2019
    Review
11. Recent evidence on delamanid use for rifampicin-resistant tuberculosis.Journal of thoracic disease · 2019
    Article
12. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.Drug development research · 2019
    Review
13. New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers.Pharmaceutics · 2018
    Review
14. Tuberculosis elimination: where are we now?European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
15. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.The European respiratory journal · 2018
    Article
16. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2018
    Review
17. Pneumonia caused by Mycobacterium tuberculosis.Microbes and infection
    Article
18. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs.Therapeutic advances in infectious disease
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

15 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as